-
Amprenavir
- indication:For the treatment of HIV-1 infection in combination with other antiretroviral agents.
- pharmacologypharmacology:
- mechanism: Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
- toxicity:
- absorprion: Rapidly absorbed after oral administration in HIV-1-infected patients with a time to peak concentration (T<sub>max</sub>) typically between 1 and 2 hours after a single oral dose. The absolute oral bioavailability of amprenavir in humans has not been established.
- halflife: 7.1-10.6 hours
- roouteelimination:
- volumedistribution:
- clearance: